Celladon develops and manufactures molecular therapies for the treatment of heart failure. Since its founding in 2000 Celladon has raised $124m in venture capital funding.
Celladon is trading on the Nasdaq as CLDN. Barclays acted as the sole book-running manager for the offering.
The $50.6m is made up from $44m raised through an initial offer of 5.5 million shares and an additional $6.6m from the underwriters’ option to purchase 825,000 additional shares of common stock to cover overallotments.
Investors in Celladon include Enterprise Partners Venture Capital, Pfizer Ventures, Lundbeckfond Ventures, Novartis Venture Funds, Johnson & Johnson Development Corporation, GBS Venture Partners, Venrock and H&Q Healthcare Investors.